EP1057024A1 - Methods using pla 2? as a marker of metastases and for the diagnosis of selected cancers - Google Patents
Methods using pla 2? as a marker of metastases and for the diagnosis of selected cancersInfo
- Publication number
- EP1057024A1 EP1057024A1 EP99934342A EP99934342A EP1057024A1 EP 1057024 A1 EP1057024 A1 EP 1057024A1 EP 99934342 A EP99934342 A EP 99934342A EP 99934342 A EP99934342 A EP 99934342A EP 1057024 A1 EP1057024 A1 EP 1057024A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- pla
- patient
- levels
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- This invention relates to use of PLA 2 as a metastatic marker for monitoring cancers which have not metastasized for the onset of metastasis and for diagnosing metastatic cancers.
- PLA 2 is demonstrated herein to be a metastatic marker for a number of different metastatic cancers including prostate, breast, colorectal, ovarian and testicular cancer.
- This invention also relates to methods of monitoring selected cancers including breast, ovarian and testicular cancel for progression, remission, response to therapy and stabilization m patients by monitoring PLA 2 levels in these patients. Further, the invention relates to methods which aide in identification of cancers, including testicular and ovarian cancer, among individuals who have not yet been diagnose ⁇ with these cancers by detection of elevated PLA 2 levels. - 2 -
- Extracellular Phospholipase A 2 (PLA 2 ) enzymes appear to mediate a variety of responses including cellular proliferation, chemotaxis and inflammation.
- the group I enzymes function in digestion and in modulating proliferation and chemotaxis.
- RASF-PLA 2 is predominantly believed to play a role in inflammatory responses including arthritis, septic shock and lung injury.
- the level of RASF-PLA 2 is regulated at the mRNA level by a variety of agents including interleukin-6, interleukin-1 and tumor necrosis factor, all of which are involved in inflammatory responses.
- PLA 2 refers to group II or RASF-PLA 2 .
- PLA 2 includes native PLA (whole or a breakdown product) , a native complex of molecules including PLA 2 , or native chemically modified PLA 2 .
- M-PLA 2 Membrane-associated phospholipase A-, M-PLA 2 , has been disclosed as one of five factors suspected to play a role in the tumor cell processes and metastasis in human breast cancer (Yamashita et al . , Surgery, 1995, 117, 601-608). Further, higher M-PLA 2 levels have been reported in breast cancer patients with distant metastasis and in patients with scirrhous carcinoma as compared to other histological types (Yamashita, Cancer, 1994, 69, 1166-1170) . PLA : has also been reported to be expressed exclusively in gastric cancer cells with a low grade of differentiation and appears to be intensified in the invading zone of the tumor (Murata et al . , Br .
- Elevated M-PLA 2 was also detected in three gastric cancer cell lines (MKN28, KATO III and AZ521), in a pancreatic cancer cell line (SUIT-2), in a colonic cancer cell line (S 1116) and a hepatoblastoma cancer cell line (HuH-6) . (Yamashita et al . , Clinica Chimica Acta , 1994, 228, 91-99) .
- patients with T2-T4 tumors or stage II-IV cancers of the lung, breast and - 3 - digestive organs had significantly higher levels of M-PLA 2 in comparison to stage I and Tl cancers.
- PLA 2 levels have also been reported to be increased in peritoneal and pleural effusions in patients with various types of cancers including gastric, breast, pancreatic, bile duct, lung, liver, esophageal and uterine cancer and cirrhotic ascites (Abe et al . , In t . J. Cancer (Pred . Oncol . ) , 1997, 74 245-250) .
- U.S. Patent 5,747,264 discloses a diagnostic assay for detection of PLA 2 protein or PLA 2 mRNA in cells, tissues or body fluids which can be used to detect the presence of cancers, and in particular, prostate cancer. This method of quantifying PLA 2 protein levels is particularly useful for discriminating benign prostatic hyperplasia and prostate cancer.
- levels of PLA 2 in a patient can be used to diagnose and monitor various cancers for the onset of metastasis. It has also been found that determining the amount of PLA 2 in a bodily fluid of a patient is useful in diagnosing various cancers and in monitoring progression, remission, response to therapy and stabilization of certain cancers in patients.
- PLA 2 is a metastatic marker for cancers, including prostate, breast, colorectal, ovarian and testicular cancer.
- It is another object of the present invention to provide a method for monitoring cancers, including breast, ovarian and testicular cancer, for progression, remission, response to therapy and stabilization in patients suffering from such cancers which comprises measuring levels of PLA 2 in biological fluid samples obtained from the patient at selected times, wherein an increase in the measured levels of PLA 2 over time is indicative of progressive cancer, a decrease in the measured levels of PLA 2 over time is indicative of remission or response to therapy of the cancer, and no change in the measured levels of PLA 2 over time is indicative of stabilization of the cancer.
- Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating cancer are of critical importance to the outcome of patients suffering from cancer. Cancer patients are closely monitored following initial therapy and during ad ⁇ uvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. Another important step m managing cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation.
- Staging of cancer would be improved by detecting new markers m cells, tissues or bodily fluids which could differentiate between different stages of invasion. Accordingly, there is a need for cancer markers which are more sensitive and specific in detecting cancer recurrence and for increasingly sensitive and accurate methods for the staging of a cancer in humans to determine whether or not such cancer has metastasized and for monitoring the progress of a cancer in a human which has not metastasized for the onset of metastasis .
- cancer of the prostate is the most prevalent malignancy m adult males, excluding skin cancer, and is an increasingly prevalent health problem m the United States. In 1996 m the United States alone, it was estimated that 41,400 deaths would result from this disease, indicating that prostate cancer is second only to lung cancer as the most common cause of death in the same population. If diagnosed and treated early, when the cancer is still confined to the prostate, however, the chances of cure are significantly - 6 - higher. Further, treatment decisions for an individual are linked to the stage of prostate cancer present in that individual. A common classification of the spread of prostate cancer has been established by the American Urological Association (AUA) . The AUA divides prostate tumors into four stages, A to D.
- AUA American Urological Association
- Stage A microscopic cancer within prostate, is further subdivided into stages Al and A2.
- Sub-stage Al is a well-differentiated cancer confined to one site within the prostate. Treatment generally includes observation, radical prostatectomy, or radiation.
- Sub-stage A2 is a moderately to poorly differentiated cancer at multiple sites within the prostate. Treatment generally includes radical prostatectomy or radiation.
- Stage B which is characterized by a palpable lump within the prostate, is also subdivided into stages Bl and B2. In sub-stage Bl the cancer forms a small nodule in one lobe of the prostate. In sub-stage B2 the cancer forms large or multiple nodules, or occurs in both lobes of the prostate.
- Stage C is a large cancer mass involving most or all of the prostate and is also further subdivided into two stages.
- Sub-stage Cl is characterized by the cancer forming a continuous mass that may extend beyond the prostate.
- Sub-stage C2 is characterized by the cancer forming a continuous mass that invades the surrounding tissue.
- Treatment for both sub-stages Cl and C2 is radiation with or without drugs to address the cancer.
- the fourth stage, Stage D is metastatic cancer and is also subdivided into two stages.
- Sub-stage Dl is characterized by the cancer appearing in the lymph nodes of the pelvis.
- Sub- stage D2 is characterized by the cancer appearing in tissues beyond the lymph nodes. Treatment for both sub-stages Dl and
- D2 is systemic drugs to address the cancer as well as pain.
- prostate cancer staging methods are limited.
- Existing methods for diagnosing prostate cancer such as prostatic specific antigen (PSA) , digital examination, and - 7 - transurethral ultrasound tests have difficulty discriminating between prostate cancer stages A, B, C, and D.
- PSA diagnostic tests detect 20-28% of patients with benign prostatic hyperplasia (BPH) and 62-81% of prostate cancer patients with PSA blood levels above approximately 99% of the normal population.
- BPH benign prostatic hyperplasia
- 62-81% of prostate cancer patients with PSA blood levels above approximately 99% of the normal population As many as 50% of prostate cancers initially staged as A2, B, or C have metastasized and are actually stage D.
- accurate identification of metastasis is important because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers .
- testicular cancer is divided into two major categories, nonseminomas and seminomas.
- staging system for nonseminomas a stage A lesion is confined to the testis; in stage B there is regional lymph node involvement in the retroperitoneum; and in stage C, there is distant metastasis.
- stage I lesion For seminomas, a stage I lesion is confined to the testis; in stage II, the lesion has spread to the retroperitoneal lymph nodes; and in stage III, the lesion has supradiaphragmatic nodal or visceral involvement.
- testicular cancer The most common symptom of testicular cancer is painless enlargement of the testis. Acute testicular pain resulting from intertesticular hemorrhage occurs in about 10% of cases. Patients are often asymptomatic upon presentation but about 10% may exhibit back pain, cough or lower extremity edema. A testicular mass or diffuse enlargement of the testis can be detected by physical examination in most cases.
- biochemical markers are used for the diagnosis and treatment of this disease including human chorionic gonadotropin (hCG) , alpha-fetoprotein and LDH . However, as evidenced by the high rate of initial misdiagnosis, better markers are required.
- Ovarian cancer often does not cause any noticeable symptoms.
- Some possible warning signals are an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40; rarely there will be abnormal vaginal bleeding.
- Periodic, complete pelvic examinations are important; a Pap test does not detect ovarian cancer. Annual pelvic exams are recommended for women over 40.
- Surgical treatment usually involves the removal of one or both ovaries, the uterus and the fallopian tubes. If the cancer is detected early, especially in younger women, it is possible that only the cancerous ovary will be removed. Radiation and chemotherapy options also are available to - 9 - prevent or slow the recurrence of the ovarian cancer or the spread of cancer to other parts of the body following surgery.
- PLA levels are significantly higher m human patients with metastatic cancer as compared to cancer which has not yet metastasized.
- D prostate cancer as compared to prostate cancer which has not yet metastasized, i.e cancer m Stage A, B, or C.
- PIA_ levels have also been demonstrated to be elevated in patients suffering from other progressive metastatic cancers such as breast cancer, colorectal cancer, testicular cancer and ovarian cancer. Accordingly, the present invention relates to methods of diagnosing metastatic cancer and monitoring cancers which have not metastasized for the onset of metastasis .
- a patient with cancer not known to have metastasized is identified. This is accomplished by a variety of means known to those of skill m the art. For example, in the case of prostate cancer, patients are typically diagnosed with prostate cancer following digital rectal examination, serum levels of prostate specific antigen
- PSA transrectal ultrasound
- needle biopsy of the prostate and surrounding tissue.
- ovarian cancer patients are typically diagnosed with ovarian cancer following pelvic examination.
- CA125 is the most widely biomarker for detection and management of epithelial ovarian cancer.
- plasma lysophosphatidic acid (LPA) levels have been suggested as a potential biomarker for ovarian cancer and other gynecological cancers (Xu et al . JAMA, 1998, 280 (8), 719-723).
- testicular cancer patients are typically diagnosed with testicular cancer following physical examination or detection of biochemical markers including human chorionic gonadotropin
- Bodily fluids useful m - 10 - the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof.
- blood it is meant to include whole blood, plasma, serum, or any derivative of blood, preferably serum.
- PLA 2 protein or mRNA levels in the sample of bodily fluid are then determined.
- Assay techniques that can be used to measure PLA 2 protein or mRNA encoding PLA 2 in a bodily fluid sample derived from a patient having cancer are well-known to those of skill in the art.
- Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, in si tu hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis ) and non-gel based approaches such as mass spectrometry or protein interaction profiling.
- RT-PCR reverse transcriptase PCR
- immunohistochemistry assays in si tu hybridization assays
- competitive-binding assays Western Blot analyses
- ELISA assays and proteomic approaches two-dimensional gel electrophoresis (2D electrophoresis ) and non-gel based approaches such as mass
- An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to PLA 2 , preferably a monoclonal antibody.
- a reporter antibody generally is prepared which binds specifically to PLA 2 .
- the reporter antibody is attached to a detectable reagent such as a radioactive, fluorescent or enzymatic marker, for example horseradish peroxidase enzyme or alkaline phosphatase.
- antibody specific to PLA 2 is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin (BSA) .
- BSA bovine serum albumin
- the bodily fluid sample to be analyzed is incubated in the dish, during which time PLA 2 binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer.
- a reporter antibody specifically directed to PLA 2 and linked to a - 11 - detectable reagent, i.e. alkaline phosphatase, is placed in the dish resulting in binding of the reporter antibody to the bound PLA 2 .
- Unattached reporter antibody is then washed out and bound reporter antibody is detected.
- the detectable reagent is alkaline phosphatase
- reagents for alkaline phosphatase activity including a colorimetric substrate are added to the dish.
- Immobilized alkaline phosphatase, linked to PLA 2 antibodies produces a colored reaction product.
- the amount of color developed in a given time period is proportional to the amount of PLA 2 protein present in the sample.
- other reporter antibodies and means for detecting these antibodies can also be used. Quantitative results typically are obtained by reference to a standard curve.
- a competition assay can also be used wherein antibodies specific to PLA 2 are attached to a solid support and labeled PLA 2 and sample obtained from the patient having cancer are passed over the solid support. The amount of label detected attached to the solid support can then be correlated to a quantity of PLA 2 in the sample.
- Nucleic acid methods can also be used to detect PLA 2 mRNA in a bodily fluid obtained from a patient having cancer.
- nucleic acid methods include, but are not limited to poly erase chain reaction (PCR), ligase chain reaction (LCR) and nucleic acid based amplification (NASABA) .
- PCR poly erase chain reaction
- LCR ligase chain reaction
- NASABA nucleic acid based amplification
- RT-PCR Reverse transcriptase PCR
- RT-PCR also provides a powerful tool useful in the detection of the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species.
- 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. - 12 -
- proteins are separated by size using an electric current.
- the current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins.
- the second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.
- a positive result indicating that the cancer in the patient being tested or monitored has metastasized is one in which bodily fluid levels of the cancer marker, PLA 2 , are elevated above an established enzyme immunoassay (EIA) cut-off of 4.5 ng/ml.
- EIA enzyme immunoassay
- alternative EIA cutoffs may be established depending upon the acceptable number of false positive or false negative results for a particular patient group.
- elevated levels of PLA 2 can be determined by comparing measured amounts in the sample of bodily fluid obtained from the human patient having cancer with amounts of this marker in the same bodily fluid type of normal human controls or previously measured amounts in the same patient.
- PLA 2 in serum is being measured in the patient, this amount is compared with the amount of PLA 2 in serum of normal human controls or the amount of PLA 2 measured in serum of the same patient previously.
- normal - 13 - human control it is meant a random grouping of males who have not been diagnosed with prostate cancer or any other type of cancer. An increase or elevation in PLA 2 in the patient versus the amount in normal human controls or the amount previously measured in the same patient is associated with a cancer which has metastasized.
- Table 1 shows the percentage of individuals identified as positive based upon measurement of PLA 2 in serum by an ELISA with an EIA cut-off of 4.5 ng/ml in normal human controls, patients having benign prostatic hyperplasia, patients having prostatitis, patients having untreated prostate cancer in Stage A, patients having untreated prostate cancer in Stage B, patients having untreated prostate cancer in Stage C, and patient newly diagnosed and treated for progressive metastasis from prostate cancer in Stage D.
- the PSA Positive value for Random Males is based upon random PSA testing. As demonstrated in this table, the percent of - 14 - individuals positive for PLA 2 increases significantly in patients with Stage D prostate cancer as compared to either normal human controls or patients with prostate cancer in Stage A, B or C . Accordingly, measurement of PLA 2 provides a useful means for diagnosing metastatic cancer and/or monitoring the onset of metastasis in patients with prostate cancer which has not yet metastasized.
- Table 2 shows the percentage of individuals identified as positive based upon measurement of PLA 2 in serum by an ELISA with an EIA cut-off of 4.5 ng/ml in patients having breast, colorectal, ovarian or testicular cancer classified as either localized, progressive metastatic, metastatic in remission or metastatic stable.
- the percent of individuals positive for PLA 2 also increases significantly in patients with progressive breast, colorectal, ovarian and testicular metastatic cancers as compared to patients with localized cancers. Accordingly, measurement of PLA 2 provides a useful means for monitoring the onset of metastasis in patients with various types of cancer, including prostate, breast, colorectal, ovarian and testicular cancer. Further, measurement of serum PLA 2 levels at the time of diagnosis of - 15 - prostate, breast, colorectal, ovarian or testicular cancer or subsequently thereafter serves as an aide not only in the diagnosis of the cancer but also in determining if the newly diagnosed cancer is metastatic.
- the percent of individuals positive for PLA 2 decreases in patients with breast, ovarian or testicular metastatic cancer that is in remission or stabilized, from the elevated percent of individuals positive for PLA 2 with progressive metastasis. Accordingly, measurement of PLA 2 provides a useful means to monitor progression, remission, response to therapy or stabilization of various cancers over time.
- Levels of PLA 2 can be determined in biological fluid samples obtained from the patient at selected times. Times for determining PLA 2 levels for monitoring the progression, remission, response to therapy or stabilization of cancer in a patient can be routinely selected by one of skill in the art in accordance with the patient's history and the type of cancer which is being monitored. An increase in the measured levels of PLA 2 in a patient over time is indicative of progressive cancer.
- a decrease in the measured levels of PLA 2 in a patient over time is indicative of remission or response to therapy of the cancer.
- No change in the measured levels of PLA 2 in a patient over time is indicative of stabilization of the cancer.
- elevated PLA 2 levels in a bodily fluid obtained from a patient are also indicative of breast, colorectal, ovarian or testicular cancer in the patient.
- the percent of individuals positive for PLA 2 with breast, colorectal, ovarian or testicular cancer that is localized, progressive metastatic, metastatic in remission, or metastatic stable is generally greater than random healthy males or females.
- the present invention also relates to methods for diagnosing cancers, and in particular ovarian cancer or testicular cancer, in a patient by measuring PLA 2 in bodily fluids of the patient suspected of suffering from cancer.
- levels of PLA 2 at least two standard deviations above levels of PLA 2 determined in healthy males are indicative of ovarian or testicular cancer.
- Levels of PLA 2 in patients suspected of suffering from ovarian or testicular cancer are determined in a biological fluid obtained from the patient in accordance with well known assays as described herein.
- Microtiter plates were prepared for assays by coating a purified monoclonal antibody (SK088-3C6.16.2; Roshak et al . , J. Biol . Chem . , 1994, 269, 25999-26005) against type II PLA 2 at a concentration of 2.0 ⁇ g/ml in 10 mM Tris-HCl buffer at pH 8.0 overnight at 2-8°C.
- a purified monoclonal antibody SK088-3C6.16.2; Roshak et al . , J. Biol . Chem . , 1994, 269, 25999-26005
- microtiter wells were then washed four times with 10 mM Tris-HCl at pH 7.5 containing 150 mM NaCl and 0.05% Tween-20 (TBS-T) and blocked with 1.0% BSA (Sigma A-7888) in 50 mM Tris-HCl at pH 8.0 for one hour at 21- 25°C (room temperature) .
- BSA Sigma A-7888
- the microtiter plates were then - 17 - washed four times again with TBS-T before immediate use in the assay.
- sample diluent (SPD) buffer 50 mM Tris-HCl at pH 8.0, 300 mM NaCl, 0.1% BSA, 0.05% Tween-20, 1% mouse serum (Jackson ImmunoResearch Labs 015-000-120), and 0.02% NaN 3 ) was added to each well. Also added to the microtiter wells at this step was 10 ⁇ l of either type II PLA, standard
- Example 2 Quantitative Assay of Prostate Specific Antigen (PSA) in Serum PSA levels in serum samples of the same patients were quantified using the TANDEM-E PSA ImmunoEnzyMetric Assay (Hybritech, Inc. Sand Diego, CA) in accordance with the manufacturer's instructions.
- PSA Prostate Specific Antigen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US111938 | 1987-10-21 | ||
US7550498P | 1998-02-23 | 1998-02-23 | |
US75504P | 1998-02-23 | ||
US11193898A | 1998-07-08 | 1998-07-08 | |
US17550498A | 1998-10-20 | 1998-10-20 | |
US175504 | 1998-10-20 | ||
PCT/US1999/003170 WO1999042830A1 (en) | 1998-02-23 | 1999-02-12 | Methods using pla2 as a marker of metastases and for the diagnosis of selected cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1057024A1 true EP1057024A1 (en) | 2000-12-06 |
EP1057024A4 EP1057024A4 (en) | 2002-10-30 |
Family
ID=27372697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99934342A Withdrawn EP1057024A4 (en) | 1998-02-23 | 1999-02-12 | Methods using pla 2? as a marker of metastases and for the diagnosis of selected cancers |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1057024A4 (en) |
JP (1) | JP3524876B2 (en) |
CA (1) | CA2320843A1 (en) |
WO (1) | WO1999042830A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
EP1718967B1 (en) * | 2004-02-03 | 2013-04-24 | Diadexus, Inc. | METHODS OF DETECTING Lp-PLA2 ACTIVITY |
JP5142288B2 (en) * | 2006-04-05 | 2013-02-13 | 公立大学法人横浜市立大学 | Prognosis determination method for prostate cancer and diagnostic agent therefor |
ATE510492T1 (en) * | 2006-06-05 | 2011-06-15 | Forth Photonics Ltd | METHOD FOR LABELING TISSUES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747264A (en) * | 1996-08-02 | 1998-05-05 | Smithkline Beechum Corporation | Method of diagnosing and monitoring prostate cancer |
CA2262624A1 (en) * | 1996-08-02 | 1998-02-12 | Smithkline Beecham Corporation | A novel method of detecting and treating cancer |
-
1999
- 1999-02-12 EP EP99934342A patent/EP1057024A4/en not_active Withdrawn
- 1999-02-12 WO PCT/US1999/003170 patent/WO1999042830A1/en not_active Application Discontinuation
- 1999-02-12 CA CA002320843A patent/CA2320843A1/en not_active Abandoned
- 1999-02-12 JP JP2000532721A patent/JP3524876B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 OGAWA M ET AL: "ELEVATION OF SERUM GROUP II PHOSPHOLIPASE A-2 IN PATIENTS WITH CANCERS OF DIGESTIVE ORGANS" Database accession no. PREV199293042492 XP002212004 & RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, vol. 74, no. 2, 1991, pages 241-244, ISSN: 0034-5164 * |
See also references of WO9942830A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999042830A1 (en) | 1999-08-26 |
JP3524876B2 (en) | 2004-05-10 |
EP1057024A4 (en) | 2002-10-30 |
CA2320843A1 (en) | 1999-08-26 |
JP2002511564A (en) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090081685A1 (en) | Methods and compositions for the detection of ovarian disease | |
JP2010513901A (en) | Cancer biomarker | |
WO2008039774A1 (en) | Extracellular and membrane-associated prostate cancer markers | |
US20180238890A1 (en) | Methods and materials for detection, diagnosis and management of ovarian cancer | |
US20200033351A1 (en) | Diagnostic methods and kits for early detection of ovarian cancer | |
JP5616892B2 (en) | Prostate cancer biomarker | |
US20100216654A1 (en) | Biomarkers of prostate cancer and uses thereof | |
JP2008502891A (en) | Use of protein PDX1 as a marker for breast cancer | |
WO2016195051A1 (en) | Plasma biomarker panel for diagnosing pancreatic cancer | |
JP3677210B2 (en) | A novel method for diagnosing, monitoring, and staging prostate cancer | |
JP4443568B2 (en) | Use of protein ASC as a marker for breast cancer | |
EP1057024A1 (en) | Methods using pla 2? as a marker of metastases and for the diagnosis of selected cancers | |
US7288383B2 (en) | Eosinophil-derived neurotoxin as a marker for ovarian cancer | |
KR102280360B1 (en) | A Composition for Diagnosing Cancer | |
KR102325731B1 (en) | A Composition for Diagnosing Cancer | |
KR102325742B1 (en) | A Composition for Diagnosing Cancer | |
US20230074311A1 (en) | Composition for cancer diagnosis | |
KR102316892B1 (en) | A Composition for Diagnosing Cancer | |
KR102280672B1 (en) | A Composition for Diagnosing Cancer | |
KR102433983B1 (en) | A Composition for Diagnosing Cancer | |
KR102433986B1 (en) | A Composition for Diagnosing Cancer | |
KR20210109726A (en) | A Composition for Diagnosing Cancer | |
TWI539161B (en) | Markers for detection of gastric cancer | |
KR20210109725A (en) | A Composition for Diagnosing Cancer | |
KR100931997B1 (en) | KLK-5 gene as a hepatocellular carcinoma tumor marker and method for diagnosing hepatocellular carcinoma using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000925 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DIADEXUS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020918 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7G 01N 33/574 A, 7G 01N 33/53 B |
|
17Q | First examination report despatched |
Effective date: 20040402 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20041013 |